Transforming Growth Factor Beta-2 (TGF-Beta 2), Human Recombinant
5 µg
$250.00
Skip to product information
Transforming Growth Factor Beta-2 (TGF-Beta 2), Human Recombinant
Catalog no.
GF-240-2
$250.00
Human Transforming Growth Factor beta2 (TGF-beta 2) is stimulatory for cells of mesenchymal origin and inhibitory for cells of epithelial or neuroectodermal origin. Mature TGF- beta2 is a disulfide-linked homodimer of two chains composed of 112 amino acid residues each. There is a 70% homology between human TGF- beta2 and human TGF- beta1. Human TGF- beta2 is produced in genetically engineered e. coli bacteria, and purified by sequential chromatography.
- Molecular weight: 25 kDa (dimeric protein)
- Purity: Over 98% pure by non-reduced SDS gel electrophoresis.
- Storage: Store at -80°C.
- Stability: Several months at -80°C.
- Biological activity: The biological activity of human TGF-&# beta2 is determined by measuring the acidification of the culture medium (Rat-1 cells) exposed to the growth factor.
- Formulation: 1 mg/mL (pH 2.5). CAUTION: Since the volume supplied is small, we advise our customers to dilute this material to a working stock solution. To remove partial aliquots in not recommended.
-
References:
1. Moustakas, A., Lin, H.Y., Henis, Y.I., Plamondon, J., O'Conner-McCourt, M.D., and Lodish, H.F., (1993) The Journal of Biological Chemistry, Vol 268, 30, October, 22215-22218.
2. Geiser, A.G., Burmester, J.K., Webbink, R., Roberts, A.B., and Sporn, M.B., (1992). The Journal of Biological Chemistry, Vol 267, 4, February, 2588-2593.
Publications using Austral Biologicals GF-240
The following scientific publications report use of TGF-β2 from Austral Biologicals:
- Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Mimura et al., Clinical Cancer Research 11(13):4898-4904 (2005).
- Keloid-derived fibroblasts are refractory to Fas-mediated apoptosis and neutralization of autocrine transforming growth factor-beta1 can abrogate this resistance. Chodon et al., American Journal of Pathology 157(5):1661-1669 (2000).
- Transforming growth factor-beta inhibits interferon-gamma secretion by lymphokine-activated killer cells stimulated with tumor cells. Naganuma et al., Neurologia Medico-Chirurgica 36(11):789-795 (1996).
- Effects of transforming growth factor betas and basic fibroblast growth factor on articular chondrocytes obtained from immobilised rabbit knees. Okazaki et al., Annals of the Rheumatic Diseases 55(3):181-186 (1996).
- Effects of the cytokines on the proliferation of and collagen synthesis by human cataract lens epithelial cells. Nishi et al., British Journal of Ophthalmology 80(1):63-68 (1996).
- Characterization of transforming growth factor-beta growth regulatory effects and receptors on bovine mammary cells. Woodward et al., Journal of Cellular Physiology 165(2):339-348 (1995).
- Effect of the cytokines on the prostaglandin E2 synthesis by lens epithelial cells of human cataracts. Nishi et al., British Journal of Ophthalmology 79(10):934-938 (1995).
- Characterization of transforming growth factor-beta (TGF-beta) receptors on BeWo choriocarcinoma cells including the identification of a novel 38-kDa TGF-beta binding glycoprotein. Mitchell et al., Molecular Biology of the Cell 3(11):1295-1307 (1992).